Advanced NanoTherapies develops drug‑coated balloon catheters that deliver a dual‑drug payload of sirolimus and paclitaxel for coronary and peripheral interventions. Their ANT nanoparticle platform provides sustained, long‑term release and higher tissue retention, enabling higher potency at lower doses without leaving any implant behind.
Funding
$4M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current drug‑coated balloon (DCB) technologies often deliver a single antiproliferative agent at relatively high doses, resulting in limited tissue retention, suboptimal long‑term efficacy, and the need for multiple procedures to prevent restenosis in coronary and peripheral artery disease.
Solution
Advanced NanoTherapies’ SirPlux™ Duo DCB utilizes the ANT nanoparticle platform to co‑deliver sirolimus and paclitaxel directly to the vessel wall. The functionalized nanoparticles enable sustained, long‑term release of both drugs, achieving higher potency at lower overall doses while leaving no permanent implant behind. Pre‑clinical data indicate improved cellular uptake, greater tissue transfer, and enhanced drug retention compared with existing DCBs. The platform is drug‑agnostic, allowing the same excipient to be adapted for other therapeutic combinations and potential applications beyond cardiovascular interventions.
Target Audience
Primary customers are interventional cardiologists, vascular surgeons, and endovascular device manufacturers seeking a high‑efficacy, implant‑free solution for coronary and peripheral artery disease.
Features
- Dual‑drug payload (sirolimus + paclitaxel) released simultaneously for synergistic antiproliferative effect
- ANT nanoparticle excipient provides sustained, long‑term drug release and high tissue retention
- Lower total drug dose achieves stent‑like patency without leaving a permanent implant
- Drug‑agnostic nanoplatform compatible with single or multiple drug formulations for future indications
- Designed for both coronary artery disease (CAD) and peripheral artery disease (PAD) interventions